Antiprogesterones
- PMID: 2070168
Antiprogesterones
Abstract
PIP: Progesterone receptor antagonists such as mifepristone (also known as RU-486) have revolutionary potential as fertility control agents. Proven uses of RU-486 include early pregnancy termination, cervical ripening, postcoital contraception, ovulation inhibition, induction of labor after fetal death, and treatment of Cushing's syndrome. Under investigation is the use of this agent as a contraceptive and for the induction of labor at term, the treatment of progesterone-dependent cancers, and manipulation of the implantation window in in vitro fertilization. Most attention has centered on RU-486's abortifacient properties. Abortion is induced in about 62% of pregnancies under 57 days of gestation. When used in combination with exogenous prostaglandin, RU-486's effectiveness as an abortifacient is increased to 95-100%. RU-486 further provides researchers with an opportunity to explore the effects of progesterone in a variety of physiological situations. When administered in the luteal phase of the menstrual cycle, RU-486 induces luteolysis and vaginal bleeding. At this stage, the agent appears to act as a progesterone against on the hypothalamic- pituitary axis. In the follicular phase,RU-486 delays ovulation and disrupts folliculogenesis.
Similar articles
-
RU 486: an overview of mifepristone and its potential applications.Contracept Rep. 1993 May;4(2):7-9. Contracept Rep. 1993. PMID: 12286473
-
Mode of action of RU 486.Ann Med. 1993 Feb;25(1):61-4. doi: 10.3109/07853899309147859. Ann Med. 1993. PMID: 8435191 Review.
-
Antigestogens.Br Med Bull. 1993 Jan;49(1):73-87. doi: 10.1093/oxfordjournals.bmb.a072607. Br Med Bull. 1993. PMID: 8324617 Review.
-
The clinical use of RU 486 (Mefipristone).Res Reprod. 1989 Oct;21(4):3. Res Reprod. 1989. PMID: 12282921
-
Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.Early Pregnancy (Cherry Hill). 2000 Oct;4(4):230-9. Early Pregnancy (Cherry Hill). 2000. PMID: 11742418 Review.
Cited by
-
Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data.Am J Obstet Gynecol. 2012 Feb;206(2):124.e1-19. doi: 10.1016/j.ajog.2011.12.003. Epub 2011 Dec 11. Am J Obstet Gynecol. 2012. PMID: 22284156 Free PMC article.
-
Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.Am J Obstet Gynecol. 2015 Dec;213(6):846.e1-846.e19. doi: 10.1016/j.ajog.2015.08.010. Epub 2015 Aug 8. Am J Obstet Gynecol. 2015. PMID: 26264823 Free PMC article.
-
The cytokine network in women with an asymptomatic short cervix and the risk of preterm delivery.Am J Reprod Immunol. 2017 Sep;78(3):e12686. doi: 10.1111/aji.12686. Epub 2017 Jun 6. Am J Reprod Immunol. 2017. PMID: 28585708 Free PMC article.
-
Progesterone to prevent spontaneous preterm birth.Semin Fetal Neonatal Med. 2014 Feb;19(1):15-26. doi: 10.1016/j.siny.2013.10.004. Epub 2013 Dec 5. Semin Fetal Neonatal Med. 2014. PMID: 24315687 Free PMC article. Review.
-
A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix.J Perinat Med. 2013 Jan;41(1):27-44. doi: 10.1515/jpm-2012-0272. J Perinat Med. 2013. PMID: 23314512 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials